Jeremy Charriot1,2, Milka Maravic3,4, Michael Huguet4, Isabelle Vachier1, Carey Suehs1, Arnaud Bourdin1,2. 1. Department of Respiratory Diseases, Univ Montpellier, CHU Montpellier, Montpellier, France. 2. University of Montpellier, PhyMedExp, INSERM, CNRS UMR, CHRU Montpellier, Montpellier France. 3. Rheumatology, Hôpital Lariboisière, APHP, Paris, France. 4. Real World Solutions, IQVIA, La Défense, France.
Abstract
BACKGROUND: Discrepancies exist between guidelines and real-life practice in severe asthma. Objectives: To establish profiles for severe asthma patients according to their maintenance therapies and identify unmet needs. METHODS: 2432 French lung specialists and allergists were invited to participate in a severe asthma survey between March and April 2018. Retrospective data were collected using an electronic case report form developed by IQVIA. RESULTS: 71 respiratory physicians and/or allergists participated in the study, providing data for 736 severe asthma patients. The annual mean rates of hospitalization and exacerbation in the previous year were 0.65 (SD = 0.5) and 2.25 (SD = 1.0), respectively. One hundred one (13.7%) patients were treated with oral steroids; the mean dosage regimen was 16.1 mg per day (SD = 11.2). ICS-LABA-LAMA triple inhaled therapy was reported for 288 patients (39%); 231 patients (31.4%) had one biologic in their maintenance treatment. Among patients hospitalized at least once in the previous year (n = 311), 89 (28.5%) were currently treated with biologics, and 61 (19.6%) with oral steroids. One hundred sixty-six patients with uncontrolled asthma and no current biologic therapy had data for "T2 status"; 78 (47%), 89 (53.6%) and 137 (82.5%) of them had treatment criteria respectively for an anti-IgE, anti-IL5-pathway or anti-IL-4/IL-13 pathway therapy; 22 (13.2%) were ineligible for any current biologic according to biomarkers. CONCLUSION: Our study updated "real-life" therapeutic management data for severe asthma in France in 2018. We highlighted a need for improved patient-phenotyping. This work also gives a striking insight of the position of current and forthcoming biologics.
BACKGROUND: Discrepancies exist between guidelines and real-life practice in severe asthma. Objectives: To establish profiles for severe asthma patients according to their maintenance therapies and identify unmet needs. METHODS: 2432 French lung specialists and allergists were invited to participate in a severe asthma survey between March and April 2018. Retrospective data were collected using an electronic case report form developed by IQVIA. RESULTS: 71 respiratory physicians and/or allergists participated in the study, providing data for 736 severe asthma patients. The annual mean rates of hospitalization and exacerbation in the previous year were 0.65 (SD = 0.5) and 2.25 (SD = 1.0), respectively. One hundred one (13.7%) patients were treated with oral steroids; the mean dosage regimen was 16.1 mg per day (SD = 11.2). ICS-LABA-LAMA triple inhaled therapy was reported for 288 patients (39%); 231 patients (31.4%) had one biologic in their maintenance treatment. Among patients hospitalized at least once in the previous year (n = 311), 89 (28.5%) were currently treated with biologics, and 61 (19.6%) with oral steroids. One hundred sixty-six patients with uncontrolled asthma and no current biologic therapy had data for "T2 status"; 78 (47%), 89 (53.6%) and 137 (82.5%) of them had treatment criteria respectively for an anti-IgE, anti-IL5-pathway or anti-IL-4/IL-13 pathway therapy; 22 (13.2%) were ineligible for any current biologic according to biomarkers. CONCLUSION: Our study updated "real-life" therapeutic management data for severe asthma in France in 2018. We highlighted a need for improved patient-phenotyping. This work also gives a striking insight of the position of current and forthcoming biologics.
Authors: Michelle M Cloutier; Paivi M Salo; Lara J Akinbami; Richard D Cohn; Jesse C Wilkerson; Gregory B Diette; Sonja Williams; Kurtis S Elward; Jacek M Mazurek; Jovonni R Spinner; Tracey A Mitchell; Darryl C Zeldin Journal: J Allergy Clin Immunol Pract Date: 2018-02-03
Authors: Lara J Akinbami; Paivi M Salo; Michelle M Cloutier; Jesse C Wilkerson; Kurtis S Elward; Jacek M Mazurek; Sonja Williams; Darryl C Zeldin Journal: J Asthma Date: 2019-03-01 Impact factor: 2.515
Authors: Sumita Khatri; Wendy Moore; Peter G Gibson; Richard Leigh; Arnaud Bourdin; Jorge Maspero; Manuel Barros; Roland Buhl; Peter Howarth; Frank C Albers; Eric S Bradford; Martyn Gilson; Robert G Price; Steven W Yancey; Hector Ortega Journal: J Allergy Clin Immunol Date: 2018-10-23 Impact factor: 10.793
Authors: Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord Journal: N Engl J Med Date: 2009-03-05 Impact factor: 91.245
Authors: Joan Sweeney; Chris E Brightling; Andrew Menzies-Gow; Robert Niven; Chris C Patterson; Liam G Heaney Journal: Thorax Date: 2012-05-11 Impact factor: 9.139